PHC Holdings Corporation changed its company name in 2018 after the curve-out from Panasonic Group in 2014. The company acquired the diabetes care business from Bayer of Germany in 2016. Last year in 2019, the anatomical pathology business from Thermo Fisher Scientific and LSI Medience Corporation have just joined PHC group. Now, with 79 subsidiaries globally, and distribution networks in 125 countries, the PHC Group is transforming into a global healthcare company. Nikkei Medical interviewed the President and CEO Michael Kloss, who says, “PHC Group is now experiencing a very exciting moment.”
PHC Group’s Growth Strategy through Active Investments
Previously, the PHC Group mainly had three business areas; the Medical Equipment Business including SBGM systems by the Japanese subsidiary PHC Corporation, the Life Sciences Business mainly with laboratory/medical support equipment including Ultra Low Temperature (ULT) freezers and incubators, and the Healthcare IT Business centering on EMR, receipt systems, and medication history systems.
However, with the acquisition of Thermo Fisher’s anatomical pathology business and LSI Medience in 2019, the PHC Group is in the midst of the transformation to a global healthcare company with a diversified business portfolio. The number of employees has doubled from approximately 5,000 before the acquisition to approximately 10,000, and consolidated sales is expected to increase significantly from approximately JPY 190 billion in the FY ending March 2019.
Additionally, the company is also making far-sighted investments, such as joint-development of next-generation CGM products with the CGM system developer/manufacturer Zhejiang POCTech of China, and development of next-generation diagnostics solution with Lunaphore Technologies SA of Switzerland, a developer of innovative equipment for cancer research and tissue diagnostics. Going forward, we will continuously invest in growth areas, and aim to become the leading provider of best-in-class precision and digital solutions in global diagnostics and life sciences, and healthcare services in Japan.